Acute lung injury in patients with COVID-19 infection
Acute lung injury in patients with COVID-19 infection
复制标题
COVID-19感染患者的急性肺损伤
DOI：
10.1002/ctm2.16
复制
发表时间：
2020-03-31
影响因子：
10.6
通讯作者：
Wang, Xiangdong
中科院分区：
文献类型：
--
作者：
Li, Liyang;Huang, Qihong;Wang, Xiangdong
2020年春节期间，中国爆发了一种新型冠状病毒，世卫组织将其命名为COVID-19，引发了全球恐慌。根据感染患者的临床资料，肺水肿的放射学证据是常见的，值得临床注意。肺水肿是急性肺损伤（ALI）的一种表现，并可能进展为低氧血症和潜在的急性呼吸窘迫综合征（ARDS）。诊断为ARDS的患者预后较差，死亡率可能更高。虽然没有正式批准的有效治疗COVID-19感染的方法，但通常需要氧气治疗和有时机械通气的通气支持。全身和/或局部糖皮质激素治疗可能有助于减轻肺部炎症和水肿，这可能会减少ARDS的发展和/或后果。在本文中，我们重点关注这种广泛传播的COVID-19感染患者的肺水肿和ALI，以便为临床医生和研究人员提供临床适应症和潜在的治疗靶点。
During the 2020 Spring Festival in China, the outbreak of a novel coronavirus, named COVID-19 by WHO, brought on a worldwide panic. According to the clinical data of infected patients, radiologic evidence of lung edema is common and deserves clinical attention. Lung edema is a manifestation of acute lung injury (ALI) and may progress to hypoxemia and potentially acute respiratory distress syndrome (ARDS). Patients diagnosed with ARDS have poorer prognosis and potentially higher mortality. Although no effective treatment is formally approved for COVID-19 infection, support of ventilation with oxygen therapy and sometimes mechanical ventilation is often required. Treatment with systemic and/or local glucocorticoids might be helpful to alleviate the pulmonary inflammation and edema, which may decrease the development and/or consequences of ARDS. In this article, we focus on the lung edema and ALI of patients with this widely transmitted COVID-19 infection in order to provide clinical indications and potential therapeutic targets for clinicians and researchers.